Overview

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

Status:
RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

Phase:

PHASE3

Details

Lead Sponsor:

Intra-Cellular Therapies, Inc.

Treatments:

lumateperone